Palliative Care in SMA Type 1: A Prospective Multicenter French Study Based on Parents' Reports

Marie Hully, Christine Barnerias, Delphine Chabalier, Sophie Le Guen, Virginie Germa, Elodie Deladriere, Catherine Vanhulle, Jean-Marie Cuisset, Brigitte Chabrol, Claude Cances, Carole Vuillerot, Caroline Espil, Michele Mayer, Marie-Christine Nougues, Pascal Sabouraud, Jeremie Lefranc, Vincent Laugel, Francois Rivier, Ulrike Walther Louvier, Julien Durigneux, Sylvia Napuri, Catherine Sarret, Michel Renouil, Alice Masurel, Marcel-Louis Viallard, Isabelle Desguerre, Marie Hully, Christine Barnerias, Delphine Chabalier, Sophie Le Guen, Virginie Germa, Elodie Deladriere, Catherine Vanhulle, Jean-Marie Cuisset, Brigitte Chabrol, Claude Cances, Carole Vuillerot, Caroline Espil, Michele Mayer, Marie-Christine Nougues, Pascal Sabouraud, Jeremie Lefranc, Vincent Laugel, Francois Rivier, Ulrike Walther Louvier, Julien Durigneux, Sylvia Napuri, Catherine Sarret, Michel Renouil, Alice Masurel, Marcel-Louis Viallard, Isabelle Desguerre

Abstract

Spinal muscular atrophy type 1 (SMA-1) is a severe neurodegenerative disorder, which in the absence of curative treatment, leads to death before 1 year of age in most cases. Caring for these short-lived and severely impaired infants requires palliative management. New drugs (nusinersen) have recently been developed that may modify SMA-1 natural history and thus raise ethical concerns about the appropriate level of care for patients. The national Hospital Clinical Research Program (PHRC) called "Assessment of clinical practices of palliative care in children with Spinal Muscular Atrophy Type 1 (SMA-1)" was a multicenter prospective study conducted in France between 2012 and 2016 to report palliative practices in SMA-1 in real life through prospective caregivers' reports about their infants' management. Thirty-nine patients were included in the prospective PHRC (17 centers). We also studied retrospective data regarding management of 43 other SMA-1 patients (18 centers) over the same period, including seven treated with nusinersen, in comparison with historical data from 222 patients previously published over two periods of 10 years (1989-2009). In the latest period studied, median age at diagnosis was 3 months [0.6-10.4]. Seventy-seven patients died at a median 6 months of age[1-27]: 32% at home and 8% in an intensive care unit. Eighty-five percent of patients received enteral nutrition, some through a gastrostomy (6%). Sixteen percent had a non-invasive ventilation (NIV). Seventy-seven percent received sedative treatment at the time of death. Over time, palliative management occurred more frequently at home with increased levels of technical supportive care (enteral nutrition, oxygenotherapy, and analgesic and sedative treatments). No statistical difference was found between the prospective and retrospective patients for the last period. However, significant differences were found between patients treated with nusinersen vs. those untreated. Our data confirm that palliative care is essential in management of SMA-1 patients and that parents are extensively involved in everyday patient care. Our data suggest that nusinersen treatment was accompanied by significantly more invasive supportive care, indicating that a re-examination of standard clinical practices should explicitly consider what treatment pathways are in infants' and caregivers' best interest. This study was registered on clinicaltrials.gov under the reference NCT01862042 (https://ichgcp.net/clinical-trials-registry/NCT01862042?cond=SMA1&rank=8).

Keywords: SMA; caregivers; ethics; palliative care; standard of care.

Copyright © 2020 Hully, Barnerias, Chabalier, Le Guen, Germa, Deladriere, Vanhulle, Cuisset, Chabrol, Cances, Vuillerot, Espil, Mayer, Nougues, Sabouraud, Lefranc, Laugel, Rivier, Louvier, Durigneux, Napuri, Sarret, Renouil, Masurel, Viallard and Desguerre.

Figures

Figure 1
Figure 1
Flowchart of the patients involved in the prospective and retrospective studies (2012–2016), as well as data from previous published French study (1989–2009).
Figure 2
Figure 2
Parents' opinion about their child's technical care.
Figure 3
Figure 3
Parents' opinion about their child's comfort.

References

    1. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. . Identification and characterization of a spinal muscular atrophy-determining gene. Cell. (1995) 80:155–65. 10.1016/0092-8674(95)90460-3
    1. Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. . Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review. Orphanet J Rare Dis. (2017) 12:124. 10.1186/s13023-017-0671-8
    1. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, et al. . Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. (1997) 16:265–69. 10.1038/ng0797-265
    1. Wirth B, Brichta L, Schrank B, Lochmuller H, Blick S, Baasner A. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. (2006) 119:422–8. 10.1007/s00439-006-0156-7
    1. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. . Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. (2018) 28:103–15. 10.1016/j.nmd.2017.11.005
    1. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. (2008) 371:2120–33. 10.1016/S0140-6736(08)60921-6
    1. Barnérias C, Quijano S, Mayer M, Estournet B, Cuisset J-M, Sukno S, et al. Amyotrophie spinale type 1: enquête multicentrique des pratiques de soins et d'accompagnement palliatif sur deux périodes successives de 10ans. Arch Pédiatrie. (2014) 21:347–54. 10.1016/j.arcped.2014.01.017
    1. Tassie B, Isaacs D, Kilham H, Kerridge I. Management of children with spinal muscular atrophy type 1 in Australia: audit of spinal muscular atrophy type 1. J Paediatr Child Health. (2013) 49:815–9. 10.1111/jpc.12291
    1. Ropars J, Barnerias C, Hully M, Chabalier D, Peudenier S, Barzic A, et al. . Thoracic circumference: a new outcome measure in spinal muscular atrophy type 1? Neuromuscul Disord. (2019) 29:415–21. 10.1016/j.nmd.2019.03.003
    1. Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. . Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. (2018) 28:197–207. 10.1016/j.nmd.2017.11.004
    1. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. . Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. (2007) 22:1027–49. 10.1177/0883073807305788
    1. Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. . Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. (2014) 83:810–87. 10.1212/WNL.0000000000000741
    1. Oskoui M, Levy G, Garland CJ, Gray JM, O'hagen J, De Vivo DC, et al. . The changing natural history of spinal muscular atrophy type 1. Neurology. (2007) 69:1931–6. 10.1212/01.wnl.0000290830.40544.b9
    1. Ryan MM. The use of invasive ventilation is appropriate in children with genetically proven spinal muscular atrophy type 1: the motion against. Paediatr Respir Rev. (2008) 9:51–4. 10.1016/j.prrv.2007.10.002
    1. Davis RH, Godshall BJ, Seffrood E, Marcus M, LaSalle BA, Wong B, et al. . Nutritional practices at a glance: spinal muscular atrophy type i nutrition survey findings. J Child Neurol. (2014) 29:1467–72. 10.1177/0883073813503988
    1. De Sanctis R, Coratti G, Pasternak A, Montes J, Pane M, Mazzone ES, et al. . Developmental milestones in type I spinal muscular atrophy. Neuromuscul Disord. (2016) 26:754–9. 10.1016/j.nmd.2016.10.002
    1. Lemoine TJ, Swoboda KJ, Bratton SL, Holubkov R, Mundorff M, Srivastava R. Spinal muscular atrophy type 1: are proactive respiratory interventions associated with longer survival? Pediatr Crit Care Med. (2012) 13:e161–5. 10.1097/PCC.0b013e3182388ad1
    1. Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, Darryl C, et al. . Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology. (2016) 86:890–7. 10.1212/WNL.0000000000002445
    1. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. . Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. (2017) 377:1723–32. 10.1056/NEJMoa1702752
    1. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. . Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. (2016) 388:3017–26. 10.1016/S0140-6736(16)31408-8
    1. Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. . Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. (2018) 378:625–35. 10.1056/NEJMoa1710504
    1. Di Pede C, Agosto C, De Tommasi V, De Gregorio A, Benini F. Symptom management and psychological support for families are the cornerstones of end-of-life care for children with spinal muscular atrophy type 1. Acta Paediatr. (2018) 107:140–4. 10.1111/apa.14086
    1. García-Salido A, de Paso-Mora MG, Monleón-Luque M, Martino-Alba R. Palliative care in children with spinal muscular atrophy type I: what do they need? Palliat Support Care. (2015) 13:313–7. 10.1017/S1478951514000042
    1. Lövgren M, Sejersen T, Kreicbergs U. Information and treatment decisions in severe spinal muscular atrophy: a parental follow-up. Eur J Paediatr Neurol. (2016) 20:830–8. 10.1016/j.ejpn.2016.08.008
    1. Higgs EJ, McClaren BJ, Sahhar MA, Ryan MM, Forbes R. A short time but a lovely little short time: Bereaved parents' experiences of having a child with spinal muscular atrophy type 1: Bereaved parents' experiences of SMA 1. J Paediatr Child Health. (2016) 52:40–6. 10.1111/jpc.12993
    1. Hjorth E, Kreicbergs U, Sejersen T, Lövgren M. Parents' advice to healthcare professionals working with children who have spinal muscular atrophy. Eur J Paediatr Neurol. (2018) 22:128–34. 10.1016/j.ejpn.2017.10.008
    1. Beernaert K, Lövgren M, Jeppesen J, Werlauff U, Rahbek J, Sejersen T, et al. Parents' experiences of information and decision making in the care of their child with severe spinal muscular atrophy: a population survey. J Child Neurol. (2019) 34:210–5. 10.1177/0883073818822900
    1. Lövgren M, Sejersen T, Kreicbergs U. Parents' experiences and wishes at end of life in children with spinal muscular atrophy types I and II. J Pediatr. (2016) 175:201–5. 10.1016/j.jpeds.2016.04.062
    1. Murrell DV, Crawford CA, Jackson CT, Lotze TE, Wiemann CM. Identifying opportunities to provide family-centered care for families with children with type 1 spinal muscular atrophy. J Pediatr Nurs. (2018) 43:111–9. 10.1016/j.pedn.2018.09.007
    1. Finkel RS, Bishop KM, Nelson RM. Spinal muscular atrophy type i: is it ethical to standardize supportive care intervention in clinical trials? J Child Neurol. (2017) 32:155–60. 10.1177/0883073816671236
    1. Burgart AM, Magnus D, Tabor HK, Paquette ED-T, Frader J, Glover JJ, et al. . Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy. JAMA Pediatr. (2018) 172:188. 10.1001/jamapediatrics.2017.4409
    1. King NMP, Bishop CE. New treatments for serious conditions: ethical implications. Gene Ther. (2017) 24:534–8. 10.1038/gt.2017.32
    1. Luzzatto L, Hyry HI, Schieppati A, Costa E, Simoens S, Schaefer F, et al. . Outrageous prices of orphan drugs: a call for collaboration. Lancet. (2018) 392:791–4. 10.1016/S0140-6736(18)31069-9
    1. Vukovic S, McAdam L, Zlotnik-Shaul R, Amin R. Putting our best foot forward: clinical, treatment-based and ethical considerations of nusinersen therapy in Canada for spinal muscular atrophy: spinal muscular atrophy and nusinersen. J Paediatr Child Health. (2019) 55:18–24. 10.1111/jpc.14226
    1. Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH, et al. Emerging therapies and challenges in spinal muscular atrophy: therapies and Challenges in SMA. Ann Neurol. (2017) 81:355–68. 10.1002/ana.24864
    1. Zuluaga-Sanchez S, Teynor M, Knight C, Thompson R, Lundqvist T, Ekelund M, et al. . Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. Pharmacoeconomics. (2019) 37:845–65. 10.1007/s40273-019-00769-6
    1. Lee M, França UL, Graham RJ, McManus ML. Pre-nusinersen hospitalization costs of children with spinal muscular atrophy. Pediatr Neurol. (2019) 92:3–5. 10.1016/j.pediatrneurol.2018.11.002
    1. Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, et al. . Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. (2016) 11:58. 10.1186/s13023-016-0424-0

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera